In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...

Children with the IL-7R variant had a lower risk of eczema if they had a pet dog in their first year of life. In fact, the genetic risk seemed to disappear entirely in babies who regularly ...

SAN DIEGO -- Patients with moderate to severe ulcerative colitis experienced clinical, endoscopic, histological, and biological improvements with the first-in-class interleukin (IL)-7 receptor ...

“As elevated mucosal IL-7/IL-7R expression predicts refractoriness to currently used biologic therapies, it would be very interesting to see the potential of lusvertikimab as a treatment for ...

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO Lusvertikimab achieved statistical significance on ...

The oral communication, entitled "Anti-IL-7 Receptor Plus Anti-IL12/23 Combination Induces Complete Histological Normalization in Chronic Colitis”, presented by Nicolas Poirier, reported that IL-7 ...

Combining Lusvertikimab with an anti-IL-23 monoclonal antibody (eg. Guselkumab) restores the inhibition of human Th17 cells in the presence of both IL-7 and IL-23. High IL-7R tissue expression has ...

The administration of anti-IL-7R in combination with an anti-IL-12/23 acts synergistically to achieve profound preclinical control of chronic colitis, characterized by complete histological healing.

NANTES, France – February 20, 2025, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today presented positive preclinical data on the combination of anti-IL-7 receptor ...

NANTES, France – February 20, 2025, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today presented positive preclinical data on the combination of anti-IL-7 receptor (IL-7R) ...